Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Icon ( (ICLR) ) has shared an announcement.
On November 12, 2025, ICON plc announced that its CEO, Barry Balfe, and CFO, Nigel Clerkin, will present at the Jefferies London Healthcare Conference on November 19, 2025. This participation underscores ICON’s active engagement in the healthcare industry and offers an opportunity to showcase its leadership in clinical research. The event is expected to enhance ICON’s visibility and strengthen its position in the market, potentially impacting stakeholders positively.
The most recent analyst rating on (ICLR) stock is a Hold with a $178.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Neutral.
Icon’s overall stock score reflects strong financial performance and strategic investments, tempered by bearish technical indicators and valuation concerns. The company’s ability to manage cash flow and address pricing pressures will be crucial for future performance.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a leading clinical research organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations, focusing on advancing clinical research from molecule to medicine. As of September 30, 2025, ICON employed approximately 39,800 employees across 95 locations in 55 countries.
Average Trading Volume: 993,827
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.26B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.